NCT00372307已完成2 期
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Repigmentation percentage of the reference lesion after 6 months.
研究概览
简要总结
Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Active or stable vitiligo vulgaris
- •lesions at head or neck + maximum 10% lesions at the rest of the body
排除标准
- •Topica during last 2 weeks
- •Photo(chemo)therapy during last 4 weeks
- •Segmentary vitiligo
结局指标
主要结局
Repigmentation percentage of the reference lesion after 6 months.
次要结局
- Number of patients with repigmentation after 3 and 6 months.
- Repigmentation percentage of the reference lesion after 3 months.
- Adverse events (month 3 and 6).
研究者
研究点 (2)
Loading locations...
相似试验
招募中
4 期
Efficacy and safety of bimatoprost in vitiligo: A randomized single-blinded controlled studyStable nonsegmental and segmental vitiligo lesions (for the last 3 months)Vitiligo,nonsegmental,segmentalTCTR20170526002Department of dermatology, Siriraj Hospital25
已完成
2 期
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis SiccaKeratoconjunctivitis SiccaNCT00128245Novartis440
已完成
4 期
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-oldAtopic DermatitisNCT00510003Novartis Pharmaceuticals117
进行中（未招募）
2 期
Daily Topical Rapamycin for VitiligoVitiligoNCT05342519Medical University of South Carolina20
已完成
2 期
Pimecrolimus Cream for Oral Lichen PlanusOral Lichen PlanusNCT00297037University of Utah21